On March 27, 2024, Ann & Robert H. Lurie Children's Hospital of Chicago treated its first patient with ELEVIDYS (delandistrogene moxeparvovec-rokl), the first gene therapy for Duchenne muscular dystrophy – a rare, genetic disease characterized by progressive muscle damage and weakness.
PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ In the pursuit of developing Novel Biologic entities, scientists harnessing the power of AI and generative .
Relief Therapeutics Holding SA Key word AGMEGM RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting 27March2024 0700 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR Th
Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences: Cell & Gene Meeting on the Med – April 9-11 ; Rome, ItalyCompany Presentation by CEO Rodolphe Clerval on April 10 at 13.45 CET LSX World Congress – April 29-30 ; London, UKCEO Rodolphe Clerval attending and available for investor meetings BioEquity Europe –